Ginkgo Bioworks Holdings (DNA) Cash & Current Investments (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Cash & Current Investments data on file, last reported at $143.9 million in Q1 2026.

• Quarterly Cash & Current Investments fell 53.95% year-over-year to $143.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.9 million (down 53.95% YoY) and the FY2025 annual result came in at $422.6 million, down 24.74% from the prior year.
• Cash & Current Investments slipped to $143.9 million in Q1 2026, from $422.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.5 billion in Q1 2022 to a low of $111.1 million in Q3 2025.
• A 5-year average of $809.1 million and a median of $840.4 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 486.14% — and 2025, when it sank 81.98%.
• Tracing DNA's Cash & Current Investments over 5 years: stood at $1.3 billion in 2022, then decreased by 28.36% to $944.1 million in 2023, then tumbled by 40.52% to $561.6 million in 2024, then slipped by 24.74% to $422.6 million in 2025, then slumped by 65.96% to $143.9 million in 2026.
• The last three Cash & Current Investments figures came in at $143.9 million (Q1 2026), $422.6 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.